Insmed Inc (INSM) Stock Analysis
Verdict: HOLD
Hyper-growth in MAC lung disease and a clear 2027 profitability path outweigh current burn; momentum is high but insider selling warns.
Investment score: 64/100
Analysis as of
Is Insmed Inc stock worth reviewing? The TradeMates thesis
INSM is a high-conviction growth play transitioning from a burning biotech to a profitable specialty pharma by 2027.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Insmed Inc opportunities and risks
What speaks for INSM
- Revenue Hyper-growth
What speaks against INSM
- Escalating Cash Burn
Frequently asked questions about Insmed Inc (INSM)
Is INSM stock a good investment?
The TradeMates model rates Insmed Inc as HOLD with an investment score of 64/100. INSM is a high-conviction growth play transitioning from a burning biotech to a profitable specialty pharma by 2027. This is algorithmic model output, not personal investment advice.
Is INSM stock a buy?
The TradeMates model verdict for INSM is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.